Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report

finance.yahoo.com/news/mercks-dealmaking-intensifies-moonlake-bid-113818105.html

In This Article:
US drug giant Merck & Co Inc (NYSE:MRK) reportedly approached Swiss biotech MoonLake Immunotherapeutics (NASDAQ:MLTX) with a bid exceeding $3 billion.
While MoonLake turned down the initial offer, talks may be revived.
The potential deal signals renewed dealmaking…

This story appeared on finance.yahoo.com, 2025-06-03 11:38:09.
The Entire Business World on a Single Page. Free to Use →